Colchicine Update: 2008

Schlesinger, 2006, Colchicine for acute gout, Cochrane Database Syst Rev, 10.1002/14651858.CD006190 Lidar, 2007, Familial Mediterranean fever: clinical, molecular and management advancements, Neth J Med, 65, 318 Terkeltaub, 2005, Pathogenesis and treatment of crystal-induced inflammation, 2357 Niel, 2006, Colchicine today, Joint Bone Spine, 73, 672, 10.1016/j.jbspin.2006.03.006 Ben-Chetrit, 1998, Colchicine: 1998 update, Semin Arthritis Rheum, 28, 48, 10.1016/S0049-0172(98)80028-0 Ferron, 1996, Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses, J Clin Pharmacol, 36, 874, 10.1002/j.1552-4604.1996.tb04753.x Rochdi, 1994, Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects, Eur J Clin Pharmacol, 46, 351, 10.1007/BF00194404 Mizutani, 2008, Genuine functions of P-glycoprotein (ABCB1), Curr Drug Metab, 9, 167, 10.2174/138920008783571756 Marchetti, 2007, Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1. P-glycoprotein), Oncologist, 12, 927, 10.1634/theoncologist.12-8-927 Loo, 2003, Substrate-induced conformational changes in the transmembrane segment of human P-glycoprotein, J Biol Chem, 278, 13603, 10.1074/jbc.C300073200 Chen, 2008, Hepatobiliary excretion and enterohepatic circulation of colchicine in rats, Int J Pharm, 350, 230, 10.1016/j.ijpharm.2007.08.052 Borron, 1996, Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors, Hum Exp Toxicol, 15, 885, 10.1177/096032719601501104 Yuan, 2008, Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance, Curr Med Chem, 15, 470, 10.2174/092986708783503258 Shukla, 2008, Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges, Exp Opin Drug Metab Toxicol, 4, 205, 10.1517/17425255.4.2.205 Li, 2007, Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms, Methods Find Exp Clin Pharmacol, 29, 607, 10.1358/mf.2007.29.9.1139054 Callaghan, 2008, P-glycoprotein: so many ways to turn it on, J Clin Pharmacol, 48, 365, 10.1177/0091270007311568 Calcagno, 2007, ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions, Curr Drug Deliv, 4, 324, 10.2174/156720107782151241 Sauna, 2007, Genomics and the mechanism of P-glycoprotein (ABCB1), J Bioenerg Biomembr, 39, 481, 10.1007/s10863-007-9115-9 Tufan, 2007, Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever, J Rheumatol, 34, 1540 Lidar, 2004, Colchicine nonresponsiveness in familial Mediterranean fever: genetic, pharmacokinetic, and socioeconomic characterization, Semin Arthritis Rheum, 33, 273, 10.1053/S0049-0172(03)00137-9 Wilbur, 2004, Colchicine myotoxicity: case reports and literature review, Pharmacotherapy, 24, 1784, 10.1592/phco.24.17.1784.52334 Simkin, 2000, Colchicine use in cyclosporine treated transplant recipients: how little is too much?, J Rheumatol, 27, 1334 Pal, 2006, MDR- and CYP3A4-mediated drug-drug interactions, J Neuroimmune Pharmacol, 1, 323, 10.1007/s11481-006-9034-2 Ingelman-Sundberg, 2007, Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects, Pharmacol Ther, 116, 496, 10.1016/j.pharmthera.2007.09.004 Nowack, 2008, Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: Grapefruit juice, St John's Wort—and beyond! Nephrology, 13, 337 Isin, 2007, Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4, J Biol Chem, 282, 6863, 10.1074/jbc.M610346200 Galetin, 2005, CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions, J Pharmacol Exp Ther, 314, 180, 10.1124/jpet.104.082826 Tang, 2001, Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions, Curr Drug Metab, 2, 185, 10.2174/1389200013338658 Hsu, 2002, Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin, Clin Neuropharmacol, 25, 266, 10.1097/00002826-200209000-00008 Alayli, 2005, Acute myopathy in a patient with concomitant use of pravastatin and colchicine, Ann Pharmacother, 39, 1358, 10.1345/aph.1E593 Akdag, 2006, Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure, J Nephrol, 19, 515 Hung, 2005, Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study, Clin Infect Dis, 41, 291, 10.1086/431592 Rollot, 2004, Acute colchicine intoxication during clarithromycin administration, Ann Pharmacother, 38, 2074, 10.1345/aph.1E197 Akdag, 2006, Acute colchicine intoxication during administration in patients with chronic renal failure, J Nephrol, 19, 515 Baker, 2004, Cytoskeletal myotoxicity from simvastatin and colchicine, Muscle Nerve, 30, 799, 10.1002/mus.20135 Tufan, 2006, Rhabdomyolysis in a patient treated with colchicine and atorvastin, Ann Pharmacother, 40, 1466, 10.1345/aph.1H064 Atasoyu, 2005, Possible colchicine rhabdomyolysis in a fluvastatin-treated patient, Ann Pharmacother, 39, 1368, 10.1345/aph.1E653 Bhattacharyya, 2008, Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin [published online ahead of print April 2007], Med Res Rev, 28, 155, 10.1002/med.20097 Wilson, 1999, Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators, Cell Struct Funct, 24, 329, 10.1247/csf.24.329 Ravelli, 2004, Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain, Nature, 428, 198, 10.1038/nature02393 Bibas, 2005, Colchicine for dermatologic diseases, J Drugs Dermatol, 4, 196 Cronstein, 2006, The inflammatory process of gout and its treatment, Arthritis Res Ther, 8, S3, 10.1186/ar1908 Nuki, 2008, Colchicine: A critical appraisal of its mechanism of action and efficacy in crystal-induced inflammation, Curr Rheumatol Rep, 10.1007/s11926-008-0036-3 Cronstein, 1995, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils, J Clin Invest, 96, 994, 10.1172/JCI118147 Mansfield, 2001, The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments, Blood, 98, 851, 10.1182/blood.V98.3.851 Yu, 2007, Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants, Mol Cell, 28, 214, 10.1016/j.molcel.2007.08.029 Rigante, 2006, The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever, Eur Rev Med Pharmacol Sci, 10, 173 Aldea, 2004, A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder?, Am J Med Genet A, 124, 67, 10.1002/ajmg.a.20296 Ben-Chetrit, 2003, Familial Mediterranean fever (FMF) and renal AA amyloidosis—phenotype-genotype correlation, treatment and prognosis, J Nephrol, 16, 431 Ben-Chetrit, 2006, Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis, Rheumatology (Oxford), 45, 274, 10.1093/rheumatology/kei140 Martinon, 2006, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, 440, 237, 10.1038/nature04516 Pétrilli, 2007, Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration, Cell Death Differ, 14, 1583, 10.1038/sj.cdd.4402195 Mizumoto, 2007, Colchicine promotes antigen cross-presentation by murine dendritic cells, J Invest Dermatol, 127, 1543, 10.1038/sj.jid.5700699 Mizumoto, 2005, Discovery of novel immunostimulants by dendritic-cell-based functional screening, Blood, 106, 3082, 10.1182/blood-2005-03-1161 Peachman, 2004, Functional microtubules are required for antigen processing by macrophages and dendritic cells, Immunol Lett, 95, 13, 10.1016/j.imlet.2004.05.013 Ahern, 1987, Does colchicine work?, Aust NZ J Med, 17, 301, 10.1111/j.1445-5994.1987.tb01232.x Borstad, 2004, Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis, J Rheumatol, 31, 2429 Becker, 2005, Febuxostat compared with allopurinol in patients with hyperuricemia and gout, N Engl J Med, 353, 2450, 10.1056/NEJMoa050373 Richette, 2007, Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study, J Rheumatol, 34, 2093 Liu-Bryan, 2006, Evil humors take their toll as innate immunity makes gouty joints TREM-ble, Arthritis Rheum, 54, 383, 10.1002/art.21634 Pascual, 1992, Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals, J Rheumatol, 19, 600 Zhang, 2006, EULAR evidence based recommendations for gout. Part II: Management Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), Ann Rheum Dis, 65, 1312, 10.1136/ard.2006.055269 Terkeltaub, 2008, Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study, Arthritis Rheum, 58 Janssens, 2008, Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial, Lancet, 371, 1854, 10.1016/S0140-6736(08)60799-0 Terkeltaub, 2003, Clinical practice, N Engl J Med, 349, 1647, 10.1056/NEJMcp030733 2007, Deaths from intravenous colchicine resulting from a compounding pharmacy error—Oregon and Washington, 2007, MMWR Morb Mortal Wkly Rep, 56, 1050 Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 198;13:804-5. Yurdakul, 2001, A double-blind trial of colchicine in Behçet's syndrome, Arthritis Rheum, 44, 2686, 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H Masuda, 1989, Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease, Lancet, 1, 1093, 10.1016/S0140-6736(89)92381-7 BenEzra, 1988, Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome, Transplant Proc, 20, 136 Aktulga, 1980, A double blind study of colchicine in Behçet's disease, Haematologica, 65, 399 Malumbres, 2006, Therapeutic opportunities to control tumor cell cycles, Clin Transl Oncol, 8, 399, 10.1007/s12094-006-0193-7 Vaina, 2006, Progressive stent technologies: new approaches for the treatment of cardiovascular diseases, Exp Opin Drug Deliv, 3, 783, 10.1517/17425247.3.6.783 Atta, 2008, Colchicine inhibits intimal hyperplasia and leukocyte VEGF expression in dogs, J Surg Res, 146, 184, 10.1016/j.jss.2007.04.029 Sabry, 2007, Prevention of chronic cyclosporine nephrotoxicity in Sprague Dawley rats: role of colchicine and omega-3-fatty acids, Int Urol Nephrol, 39, 271, 10.1007/s11255-006-9061-1 Sabry, 2006, Colchicine vs. omega-3 fatty acids for prevention of chronic cyclosporine nephrotoxicity in Sprague Dawley rats: an experimental animal model, Arch Med Res, 37, 933, 10.1016/j.arcmed.2006.07.001 Li, 2002, Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity, J Lab Clin Med, 139, 364, 10.1067/mlc.2002.124397 Li, 2002, Colchicine suppresses osteopontin expression and inflammatory cell infiltration in chronic cyclosporine nephrotoxicity, Nephron, 92, 422, 10.1159/000063299 Misra, 2003, Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles, Am J Physiol Gastrointest Liver Physiol, 285, G316, 10.1152/ajpgi.00048.2003 Liu, 2005, Colchicine sensitizes human hepatocellular carcinoma cells to damages caused by radiation, World J Gastroenterol, 21, 4237, 10.3748/wjg.v11.i27.4237 Arrieta, 2006, Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis, Cancer, 15, 1852, 10.1002/cncr.22198 Bisoendial, 2007, C-reactive protein and atherogenesis: from fatty streak to clinical event, Atherosclerosis, 195, e10, 10.1016/j.atherosclerosis.2007.04.053 Nidorf, 2007, Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease, Am J Cardiol, 99, 805, 10.1016/j.amjcard.2006.10.039 Imazio, 2005, Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute pericarditis (COPE) trial, Circulation, 112, 2012, 10.1161/CIRCULATIONAHA.105.542738 Maisch, 2004, Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology, Eur Heart J, 25, 587, 10.1016/j.ehj.2004.02.002 Imazio, 2005, Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial, Arch Intern Med, 165, 1987, 10.1001/archinte.165.17.1987 Artom, 2005, Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis, Eur Heart J, 26, 723, 10.1093/eurheartj/ehi197 Imazio, 2007, Pathogenesis, management, and prevention of recurrent pericarditis, J Cardiovasc Med, 8, 404, 10.2459/01.JCM.0000269708.72487.34 Imazio, 2007, Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design and rationale, J Cardiovasc Med, 8, 613, 10.2459/01.JCM.0000281702.46359.07 Ahmed, 2006, Colchicine glycorandomization influences cytotoxicity and mechanism of action, J Am Chem Soc, 128, 14224, 10.1021/ja064686s Lee, 2007, Colchicine-derived compound CT20126 promotes skin allograft survival by regulating the balance of Th1 and Th2 cytokine production, Exp Mol Med, 39, 230, 10.1038/emm.2007.26